Steven Pearson, president of the Institute for Clinical and Economic Review (ICER), in a recent commentary dives into why the quality-adjusted life year, or QALY, is a metric worth keeping.
Pearson writes that clinical studies frequently measure health gains through “disease-specific measures” like strokes avoided or decreased pain.
“Although useful for measuring effects and comparing treatments within single conditions, such measures do not permit comparison across diseases,” Pearson writes. “The QALY is the best single measure through which we can make this kinds of comparisons … .”
To read the full article online, click here.